Skip to main content
Premium Trial:

Request an Annual Quote

Startup Cadex Genomics Raises $1.5M

NEW YORK (GenomeWeb) — Startup Cadex Genomics today announced it has raised $1.5 million in seed financing, which it will use to expand clinical studies, acquire intellectual property, and further its business plan.

The financing was led by the Redwood City, California-based firm's founders, and a group of angel investors, comprising mostly physicians. Its lead product is a blood-based assay, called Alibrex, for monitoring stage IV solid tumor cancer therapy. The test uses a routine venous blood draw and leverages PCR technology to assess whether the therapy is working within two weeks after a patient has started the regimen, allowing an oncologist to adjust the treatment, Cadex said.

The firm, founded in 2018, also announced Sudhir Sinha has joined Cadex as its chief science officer. Additionally, it named Greg Schafer its chief commercial officer, Gary Spitzer as chief medical officer, and Patrick Hall as senior vice president of medical affairs. Bill Haack is Cadex's CEO. He, Schafer, and Hall previously worked at Genomic Health to help commercialize that firm's Oncotype DX Breast assay.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.